Products & Services · Potential achievements
Boehringer Ingelheim — Potential achievements
Eli Lilly Boehringer Ingelheim — Potential achievements increased by 61.0% to $660.00M in Q1 2026 compared to the prior quarter. This is a positive signal — higher values indicate stronger performance for this metric.
Analysis
StatementSegment
CategoryGrowth
SignalHigher is better
VolatilityModerate
First reportedQ1 2025
Last reportedQ1 2026Apr 30, 2026
How to read this metric
An increase indicates successful commercialization or clinical advancement of shared assets, while a decrease may signal regulatory delays, competitive pressure, or declining market share for these specific products.
Detailed definition
This metric tracks the performance and strategic milestones associated with the partnership or product portfolio shared...
Peer comparison
Comparable to joint venture revenue, milestone payments, or royalty income reported by other pharmaceutical companies engaged in strategic R&D and commercial alliances.
Metric ID:
lly_segment_boehringer_ingelheim_potential_achievementsHistorical Data
3 periods
| Q1 '25 | Q3 '25 | Q1 '26 | |
|---|---|---|---|
| Value | $610.00M | $410.00M | $660.00M |
| QoQ Change | — | -32.8% | +61.0% |
| YoY Change | — | — | +8.2% |
Range$410.00M – $660.00M
Avg YoY Growth+8.2%
Median YoY Growth+8.2%
Similar Metrics at Other Companies
Frequently Asked Questions
- What is Eli Lilly's boehringer ingelheim — potential achievements?
- Eli Lilly (LLY) reported boehringer ingelheim — potential achievements of $660.00M in Q1 2026.
- What does boehringer ingelheim — potential achievements mean?
- This metric measures the financial and operational success of products or programs developed in partnership with Boehringer Ingelheim.